Form 4: Iovance Biotherapeutics Executive Vogt Reports Stock Transactions
SEC Form 4 Filing
Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.
Summary
- On March 4, 2024, Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, had 41,662 restricted stock units (RSUs) vest.
- The company withheld 11,449 shares at a price of $16.96 to cover mandatory tax withholding requirements.
- Following these transactions, Vogt directly owns 129,351 shares of common stock and 83,338 restricted stock units.
- The remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by an executive, with no inherently positive or negative implications for the company's overall prospects.
Future Outlook
The remaining RSUs will vest in equal quarterly installments.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO or General Counsel, trade their company's stock. These filings provide transparency into the transactions of company leadership.
Key Dates
| Date | Description |
|---|---|
| 03/02/2023 | Date of grant for the reported RSUs. |
| 03/04/2024 | Date of RSU vesting and share withholding for taxes. |
| 03/06/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.